Pharma Marketing Network
JULY 7, 2020
Great digital should be personal. As the Covid-19 environment continues to cause brands to shift more heavily toward digital and increase their non-physical tactics, it is important to remember this. We must work hard to keep these interactions personal. Personalization of content, experiences, and support services is already a mainstay of ecommerce and retail.
Eye on FDA
JULY 8, 2020
I don’t usually publish the scheduling of an AdComm with a blog posting. But this one merits one. With fewer than the usual minimum of fifteen days’ notice, FDA has scheduled an FDA Advisory Committee meeting of the Cardiovascular and Renal Drugs Advisory Committee to discuss a new drug application (NDA) for terlipressin, lyophilized power for solution for injection for the proposed indication of the treatment of hepatorenal syndrome.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JULY 9, 2020
This week (Monday through Thursday), I’m rerunning some popular posts. Click here to see the original post and comments from April 2020. In Drug Channels Institute's list of the top 15 pharmacies of 2019 , we show that many of the largest U.S. pharmacies are now central-fill mail and specialty pharmacies operated by PBMs and insurers. To complement that broader ranking, we present below our exclusive list of the top 15 pharmacies based on specialty drug dispensing revenues.
Pharmacy Joe
JULY 8, 2020
In this episode, I’ll discuss whether immediate vs early antibiotic administration improves outcomes in severe sepsis. Episode 520: Does immediate vs early antibiotic administration improve outcomes in severe sepsis? Subscribe on iTunes , Android , or Stitcher For patients with severe sepsis, it is logical to start antibiotic therapy as soon as possible.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Med Ed 101
JULY 8, 2020
Pulmonary toxicology involves the airways, lung parenchyma, mediastinum, pleura, pulmonary vasculature, and the neuromuscular system based on the route of exposure to the offending agent and the dose and duration of exposure. Acute pulmonary reactions are commonly manifested by fever, chills, cough, chest pain, dyspnea, pulmonary infiltration with consolidation or pleural effusion on x-ray, and […].
Pharma in Brief
JULY 7, 2020
The Patented Medicine Prices Review Board ( PMPRB or Board ) has found that a patent can pertain to a medicine based on clinical similarities to the invention—even if the patent does not actually encompass the medicine. Background. This case concerns Canadian Patent No. 2,478,237 (the 237 Patent ), which relates to the use of adapalene to treat dermatological disorders.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Pharmacy Joe
JULY 5, 2020
In this episode, I’ll discuss new compatibility information for IV hydrocortisone infusions. Episode 519: Additional compatibility information for IV hydrocortisone infusions Subscribe on iTunes , Android , or Stitcher Current Surviving Sepsis Campaign Guidelines recommend giving hydrocortisone 200 mg per day to patients with septic shock and inadequate response to vasopressor therapy.
Med Ed 101
JULY 5, 2020
Recently, the International Society of Hypertension released its 2020 blood pressure guidelines. Their guidelines do vary a little bit from the 2017 ACC/AHA guidelines that were put out a few years ago. Here are a few of the important highlights from the ISH 2020 blood pressure guidelines. Blood Pressure Classification Classification of hypertension based on […].
Eye on FDA
JULY 7, 2020
At mid-year, it has been a custom here at Eye on FDA to look back at a few categories of activity by FDA at the first half of the year and discern what it tells us about future directions. This year the unprecedented circumstances presented by the COVID-19 pandemic make it particularly interesting this year. A good place to start is with regulatory enforcement of the Office of Prescription Drug Promotion (#OPDP).
Drug Channels
JULY 7, 2020
This week (Monday through Thursday), I’m rerunning some popular posts. Click here to see the original post and comments from February 2020. Pharmacy-related price concessions in Medicare Part D—known as pharmacy DIR fees --have grown faster than most people realize. We estimate that these payments reached $9.1 billion in 2019. This figure indicates that about 18% of total Medicare Part D rebates are now paid by pharmacies, not manufacturers.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Channels
JULY 10, 2020
Today’s guest post comes from Rick Fry, Senior Vice President of Commercial Solutions and Jason Zemcik, Senior Director of Product Management at TrialCard. Rick and Jason outline their view of the crucial issues in the new proposed rule from Centers for Medicare and Medicaid Services (CMS) regarding copay accumulator adjustment programs. They preview the public comments that TrialCard expects to submit to CMS.
Drug Channels
JULY 6, 2020
This week (Monday through Thursday), I’m rerunning some popular posts. Click here to see the original post and comments from March 2020. Next week, Drug Channels Institute will release our 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 11th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system.
Drug Channels
JULY 6, 2020
This week (Monday through Thursday), I’m rerunning some popular posts. Click here to see the original post and comments from March 2020. Next week, Drug Channels Institute will release our 2020 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers. It’s the 11th edition of our popular and comprehensive examination of the entire drug pricing, reimbursement, and dispensing system.
Expert insights. Personalized for you.
69 
Let's personalize your content